The U.S. FDA has approved an expanded indication for Sanofi’s Toujeo for blood sugar control in adult and pediatric patients who are ages six years and older. Previously, Toujeo was approved only for adults aged 18 years and older. The company announced the results of the clinical trial earlier in the month. It was the first randomized, controlled trial to compare Toujeo to Gla-100 in this patient population. The trial met its primary endpoint, demonstrating comparable decreases in average blood sugar over six months with both treatments and similar risk of low blood sugar events. Based on the data, the EMA’s Committee for Medicinal Products for Human Use recommended the expanded label in Europe. Learn More